Human Papillomavirus (HPV) Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer in New Zealand

GlaxoSmithKline244 enrolled

Overview

The aim of this study is to assess the distribution of the most frequent types of human papillomavirus in women diagnosed with invasive cervical cancer in New Zealand.

Study Type

OBSERVATIONAL

Enrollment

244

Conditions

Cervical Cancer

Interventions

Testing of archived cervical cancer tissue samplesOTHER

Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.

Data collectionOTHER

Log sheet

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * A female aged 18 years and above at the time of cervical specimen collection, and currently residing in New Zealand. * Histological diagnoses of invasive cervical cancer stage IB or greater, within at least the last 3 years. * Written informed consent obtained from the subject/ next of kin/ Legally acceptable representative. * Availability of cervical specimen on which the diagnosis was made prior to any chemotherapy or radiotherapy. * The cervical specimen should be of appropriate size and with regular tissue specimens. * The cervical specimen should be adequately preserved. * All links to the subject's identity should be removed from the paraffin block. Exclusion Criteria: Not Applicable.

Outcomes

Primary Outcomes

Occurrence of HPV-16 and HPV-18 in women with invasive cervical cancer

Time frame: At least the last 3 years from the time of study start

Secondary Outcomes

Occurrence of other high-risk HPV types in women with invasive cervical cancer

Time frame: At least the last 3 years from the time of study start

Occurrence of HPV-16/ HPV-18 co-infection with other high-risk HPV types in women with invasive cervical cancer

Time frame: At least the last 3 years from the time of study start

Occurrence of low-risk HPV types in women diagnosed with invasive cervical cancer

Time frame: At least the last 3 years from the time of study start

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.